Scienture Holdings, Inc. SCNX
Scienture Holdings, Inc. (Nasdaq: SCNX) is a cardio-renal-metabolic specialty pharmaceutical company. Its next catalyst on record is SCN-104: Initiate Phase 1 single-dose study in healthy adults (after IND clearance) (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SCN-104 — Initiate Phase 1 single-dose study in healthy adults (after IND clearance) (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SCN-102 (ARBLI) | Hypertension | small molecule | — |
| SCN-110 (REZENOPY, naloxone nasal spray 10mg) | Opioid overdose | small molecule | — |
| SCN-104 (DHE multi-dose injection pen) | Acute migraine / cluster headache | device-combination | Phase 1 start early 2027 after IND |
| SCN-106 (biosimilar alteplase, Cathflo reference) | Catheter occlusion | biologic-other | — |
| SCN-107 (bupivacaine long-acting injection) | Postsurgical analgesia | small molecule | IND 2027 |
Recent results and decisions
- Oct 19, 2026n/a Scienture regained compliance with Nasdaq minimum bid price requirement after maintaining closing bid price at or above $1.00 for ten consecutive trading days.
Nasdaq has determined that the closing bid price of the Company's shares of common stock was at least $1.00 per share for the ten consecutive trading days between October 5, 2026 and October 16, 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved cardio-renal-metabolic companies
- ELI LILLY & Co LLY
- Amgen Inc AMGN
- Amarin Corp Plc\uk AMRN
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.